Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Regeneron, Near-Term PCSK9 Filing, Eylea Growth Point To Rapidly Improving Prospects

This article was originally published in The Pink Sheet Daily

Executive Summary

Regeneron and partner Sanofi estimate there are more than 60 million addressable patients for LDL-lowering therapy in the U.S. and EU, including 22 million at very-high risk for a cardiovascular event. Meanwhile, a label addition for diabetic macular edema heightens the sales-growth prospects for Eylea.


Related Content

Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
Preparing For Battle: PCSK9 Sponsors Stake Their Ground


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts